¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

Indexada en:

Index Medicus/MEDLINE, Excerpta Medica/EMBASE, SCOPUS, Science Citation Index Expanded, Journal Citation Reports/Science Edition, IBECS


  • Factor de Impacto: 1,106(2016)
  • SCImago Journal Rank (SJR):0,314
  • Source Normalized Impact per Paper (SNIP):0,383

© Thomson Reuters, Journal Citation Reports, 2016

Endocrinol Nutr 2006;53:450-2 - DOI: 10.1016/S1575-0922(06)71130-5
Notas clínicas
Beneficios de la metformina en el embarazo de las mujeres con síndrome del ovario poliquístico: a propósito de un caso
Benefits of metformin in pregnant women with polycystic ovary syndrome: a case report
Teresa Pedro Font, Francisco Javier Ampudia-Blasco??, , Rafael Carmena
Unidad de Referencia de Diabetes. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario. Valencia. España
Recibido 25 noviembre 2005, Aceptado 23 enero 2006

Polycystic ovary syndrome (PCOS) is a frequent disease that affects 5-10% of women of reproductive age. This entity has been associated with metabolic disturbances, such as type 2 diabetes and obesity, and alterations of the reproductive axis due to insulin resistance and hyperinsulinism, among other factors. In pregnant women with PCOS, metformin therapy has been associated with a reduction in spontaneous abortion due to improved endometrial function and embryo implantation. Furthermore, the drug reduces the frequency of gestational diabetes mellitus, which is generally increased in pregnant women with PCOS. We describe a case of term pregnancy in a woman with PCOS and type 2 diabetes, who was treated with metformin during the fertilization period and the first half of pregnancy, following three failed attempts in which the drug was discontinued before in vitro fertilization.

Palabras clave
Síndrome del ovario poliquístico, Metformina, Diabetes tipo 2, Gestación, Aborto
Key words
Polycystic ovary syndrome, Metformin, Type 2 diabetes, Pregnancy, Abortion
El Texto completo solo está disponible en PDF
C.J. Glueck,R. Papanna,P. Wang,N. Goldenberg,L. Sieve-Smith
Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome
Metabolism, 52 (2003), pp. 908-915
P. Moghetti,R. Castello,C. Negri,F. Tosi,F. Perrone,M. Caputo
Metformin effects on clinical features, endocrine and metforminabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
J Clin Endocrinol Metab, 85 (2000), pp. 139-146 http://dx.doi.org/10.1210/jcem.85.1.6293
S. Palomba,F. Orio,A. Falbo,F. Manguso,T. Russo,T. Cascella
Prospective parallel randomized, double-blind, doubledummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome
J Clin Endocrinol Metab, 90 (2005), pp. 4068-4074 http://dx.doi.org/10.1210/jc.2005-0110
S.B. Kjøtrød,V. Von During,S.M. Carlsen
Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study
Hum Reprod, 19 (2004), pp. 1315-1322
G. Önalan,R. Pabuçcu,U. Goktolga,T. Ceyhan,T. Bagis,M. Cincik
Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial
Fertil Steril, 84 (2005), pp. 798-801 http://dx.doi.org/10.1016/j.fertnstert.2005.03.043
D.J. Jakubowicz,M.J. Iuorno,S. Jakubowicz,K.A. Roberts,J.E. Nestler
Effects of metformin on early pregnancy, loss in the polycystic ovary syndrome
J Clin Endocrinol Metab, 87 (2002), pp. 524-529 http://dx.doi.org/10.1210/jcem.87.2.8207
H.S. Liddell,K. Sowden,C.M. Farquhar
Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome
Aust N Z J Obstet Gynaecol, 37 (1997), pp. 402-406
D.J. Jakubowicz,M. Seppala,S. Jakubowicz,O. Rodríguez-Armas,A. Rivas-Santiago,H. Koistinen
Insulin reduction with metformin increases luteal phase serum glycodelin and insulinlike growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome
J Clin Endocrinol Metab, 86 (2001), pp. 1126-1133 http://dx.doi.org/10.1210/jcem.86.3.7295
E.M. Velázquez,S.G. Mendoza,P. Wang,C.J. Glueck
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patientes with the polycystic ovary syndrome
Metabolism, 46 (1997), pp. 454-457
C.J. Glueck,P. Wang,N. Goldenberg,L. Sieve-Smith
Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin
Hum Reprod, 17 (2002), pp. 2858-2864
C.J. Glueck,N. Goldenberg,J. Pranikoff,M. Loftspring,L. Sieve,P. Wang
Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy
Hum Reprod, 19 (2004), pp. 1323-1330 http://dx.doi.org/10.1093/humrep/deh263
Correspondencia: Dr. F.J. Ampudia-Blasco. Unidad de Referencia de Diabetes. Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario. Avda. Blasco Ibáñez, 17. 46010 Valencia. España.
Copyright © 2006. Sociedad Espa??ola de Endocrinolog??a y Nutrici??n